AEMD · Aethlon Medical Inc.
AI read · Bad for AEMD
The AI's read
The planned merger could give Aethlon a path into North Immunology, but it has not closed. Aethlon plans workforce cuts and may wind down parts of its old business if the deal closes. The company had $6.5 million in cash, but quarterly operating costs rose to $2.7 million. Its cancer study has treated 8 patients, with only 1 more planned, and recruitment may end with the merger. Possible payments from its old business are not assured.